Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

(2020) Alessandro Rambaldi et al.   LEUKEMIA

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis

(2019) T. Demuynck et al.   ANNALS OF HEMATOLOGY

Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea

(2019) Abdulraheem Yacoub et al.   BLOOD

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions

(2019) Ruochen Jia et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

(2018) Tiziano Barbui et al.   LEUKEMIA

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

(2018) Tiziano Barbui et al.   Blood Cancer Journal

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline

(2018) Mary Frances McMullin et al.   BRITISH JOURNAL OF HAEMATOLOGY

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Histological effects of givinostat in boys with Duchenne muscular dystrophy

(2016) Paolo Bettica et al.   NEUROMUSCULAR DISORDERS

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

(2015) S Cerquozzi et al.   Blood Cancer Journal

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

(2014) H. L. Geyer et al.   BLOOD

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

(2013) Guido Finazzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells

(2012) Ariel Amaru Calzada et al.   EXPERIMENTAL HEMATOLOGY

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients

(2012) Ariel Amaru Calzada et al.   EXPERIMENTAL HEMATOLOGY

Unknown

(2011) Evelien Bodar et al.   MOLECULAR MEDICINE

Unknown

(2011) Antonio Furlan et al.   MOLECULAR MEDICINE

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA